DUBLIN--(BUSINESS WIRE)--The "Avita Medical Ltd (AVH) - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.
Summary
Avita Medical Ltd (Avita Medical) is a medical device company that develops and distributes regenerative, tissue-engineered products for treating burns, scars, wounds, and skin defects. The company's medical device portfolio includes ReCell for the treatment of burns and plastic reconstructive procedures; ReGenerCell for chronic wounds including leg and foot ulcers; and ReNovaCell for aesthetic applications including the restoration of pigmentation. Avita Medical distributes its products through its direct sales force in Australia and through distributors in the UK, France, Germany, Austria, Switzerland, Turkey, China, Japan, Taiwan, Saudi Arabia, South Korea and the US. Avita Medical is headquartered in London, the UK.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Avita Medical Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Key Topics Covered:
- Avita Medical Ltd Company Overview
- Avita Medical Ltd Company Snapshot
- Avita Medical Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Avita Medical Ltd - Pipeline Analysis Overview
- Business Description
- Avita Medical Ltd - Key Facts
- Avita Medical Ltd - Major Products and Services
- Avita Medical Ltd Pipeline Products by Development Stage
- Avita Medical Ltd Ongoing Clinical Trials by Trial Status
- Avita Medical Ltd Pipeline Products Overview
- ReCell - Diabetic Foot Ulcers
- Recell - Epidermolysis Bullosa
- Recell - Hutchinson-Gilford Progeria Syndrome
- RECELL - Soft Tissue Reconstruction
- RECELL - Soft Tissue Reconstruction Clinical Trial
- ReCell - Thermal Burns Pediatrics
- ReCell - Thermal Burns Pediatrics Clinical Trial
- ReCell - Trauma Wounds
- ReCell - Venous Leg Ulcers
- RECELL System - Vitiligo
- RECELL System - Vitiligo Product Overview
- RECELL System - Vitiligo Clinical Trial
- Avita Medical Ltd - Key Competitors
- Avita Medical Ltd - Key Employees
- Avita Medical Ltd - Key Employee Biographies
- Avita Medical Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Recent Developments
- Avita Medical Ltd, Recent Developments
- Nov 17, 2019: AVITA medical names David McIntyre as Chief Financial Officer
- Oct 31, 2019: AVITA Medical reports first quarter fiscal 2020 financial results and company update
- Sep 30, 2019: AVITA Medical announces listing on Nasdaq
- Sep 19, 2019: New data published in Aesthetic Plastic Surgery explores the use of the Recell System in combination with dermabrasion to treat acne scars
- Jul 30, 2019: AVITA Medical reports fourth quarter fiscal 2019 financial results and company update
- Jun 30, 2019: RECELL System feasibility study results for treatment of diabetic foot ulcers presented at 11th Annual Congress of the Japanese Society of Limb Salvage & Podiatric Medicine
- Jun 11, 2019: AVITA Medical announces RECELL System preliminary data focused on vitiligo and facial acne slogy
- May 16, 2019: Health economic model published in Advances in Therapy demonstrates reduced cost and decreased hospital stay with the RECELL System
- May 15, 2019: AVITA Medical appoints interim CFO
- Apr 29, 2019: AVITA Medical third quarter fiscal 2019 quarterly cash flow report and company update
- Appendix
- Methodology
- About the Author
- Contact Us
- Disclaimer
Companies Mentioned
- Smith & Nephew Plc
- Probiotec Ltd
- Pfizer SA de CV
- Organogenesis Inc
- Living Cell Technologies Ltd
- Johnson & Johnson
- Alchemia Ltd
For more information about this company profile visit https://www.researchandmarkets.com/r/hu9x6y
